clonoSEQ[®] By Adaptive

Multiple myeloma. CLL. B-ALL. It's a journey. **PINPOINT WHERE YOUR BLOOD CANCER STANDS WITH clonoSEQ®.**

clonoSEQ measures minimal residual disease (MRD) which may help you and your doctor monitor, manage, and move forward with your blood cancer care.

clonoSEQ is the first and only FDA-cleared test that detects, counts, and tracks MRD in bone marrow samples from patients with multiple myeloma or B-ALL and blood or bone marrow samples from patients with CLL.¹

Talk with your doctor about clonoSEQ

Here are some questions to help you start a conversation with your doctor about how MRD testing with clonoSEQ can help inform your treatment plan.



- What is MRD?
- Is MRD testing with clonoSEQ right for me?
- I heard that clonoSEQ can identify 1 cancer cell out of 1 million cells with sufficient sample.¹ Why does this matter for someone like me?
- What can MRD testing with clonoSEQ tell me about my cancer?
- How will MRD results from a clonoSEQ test affect my treatment plan?
- How often should I get a clonoSEQ test?
- What does a positive or negative MRD status with clonoSEQ mean for me?
- Is the goal of MRD negativity with clonoSEQ right for me?

Please visit <u>clonoSEQ.com/patients</u> for more information.

clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

References to "cancer" refer specifically to multiple myeloma, CLL, and B-ALL. References to "sample" refer to bone marrow from patients with multiple myeloma or B-ALL and bone marrow or blood from patients with CLL. Talk to your doctor about your options if you have another type of blood cancer and are interested in MRD testing.





 $\label{eq:linear} \textbf{1. clonoSEQ}^{\circledast}. \ [technical summary]. \ Seattle, \ WA: \ Adaptive \ Biotechnologies; \ 2020.$

Copyright © 2022 Adaptive Biotechnologies Corp. All rights reserved. PM-US-cSEQ-0426-3

